Skip to content
10-K

Annual Report

NEUMORA THERAPEUTICS, INC. NMRA

0001193125-26-130388

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 23, 2026 182.04M sh
Shares Diluted FY 2025 · Dec 31, 2025 163.39M sh
Shares Diluted FY 2025 · Dec 31, 2024 159.38M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$206.44M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$182.94M
Long Term Debt FY 2025 · Dec 31, 2025 $54.53M
Short Term Debt FY 2025 · Dec 31, 2025 $60M
Cash And Equivalents FY 2025 · Dec 31, 2025 $182.53M
Cash And Equivalents FY 2025 · Dec 31, 2024 $142.15M
Stockholders Equity FY 2025 · Dec 31, 2025 $103.87M
Stockholders Equity FY 2025 · Dec 31, 2024 $287.06M
Stockholders Equity FY 2025 · Dec 31, 2023 $469.08M
Current Liabilities FY 2025 · Dec 31, 2025 $32.45M
Current Liabilities FY 2025 · Dec 31, 2024 $29.89M
Total Liabilities FY 2025 · Dec 31, 2025 $87.18M
Total Liabilities FY 2025 · Dec 31, 2024 $29.91M
Current Assets FY 2025 · Dec 31, 2025 $190.54M
Current Assets FY 2025 · Dec 31, 2024 $314.06M
Total Assets FY 2025 · Dec 31, 2025 $191.05M
Total Assets FY 2025 · Dec 31, 2024 $316.97M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.45
Eps Diluted FY 2025 · Dec 31, 2024 −$1.53
Eps Basic FY 2025 · Dec 31, 2025 −$1.45
Eps Basic FY 2025 · Dec 31, 2024 −$1.53
Sga Expense FY 2025 · Dec 31, 2025 $60.09M
Sga Expense FY 2025 · Dec 31, 2024 $62.54M
Rd Expense FY 2025 · Dec 31, 2025 $176.07M
Rd Expense FY 2025 · Dec 31, 2024 $200.93M
Net Income FY 2025 · Dec 31, 2025 −$236.93M
Net Income FY 2025 · Dec 31, 2024 −$243.79M
Operating Income FY 2025 · Dec 31, 2025 −$241.16M
Operating Income FY 2025 · Dec 31, 2024 −$263.46M